These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. Evans M; Palaka E; Furuland H; Bennett H; Linde C; Qin L; McEwan P; Bakhai A BMC Nephrol; 2019 Jan; 20(1):31. PubMed ID: 30704421 [TBL] [Abstract][Full Text] [Related]
4. Epidemiology of hyperkalemia in chronic kidney disease. Belmar Vega L; Galabia ER; Bada da Silva J; Bentanachs González M; Fernández Fresnedo G; Piñera Haces C; Palomar Fontanet R; Ruiz San Millán JC; de Francisco ÁLM Nefrologia (Engl Ed); 2019; 39(3):277-286. PubMed ID: 30898450 [TBL] [Abstract][Full Text] [Related]
5. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. Furuland H; McEwan P; Evans M; Linde C; Ayoubkhani D; Bakhai A; Palaka E; Bennett H; Qin L BMC Nephrol; 2018 Aug; 19(1):211. PubMed ID: 30134846 [TBL] [Abstract][Full Text] [Related]
6. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives. Llubani R; Vukadinović D; Werner C; Marx N; Zewinger S; Böhm M Curr Heart Fail Rep; 2018 Dec; 15(6):390-397. PubMed ID: 30421355 [TBL] [Abstract][Full Text] [Related]
7. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. Bianchi S; Aucella F; De Nicola L; Genovesi S; Paoletti E; Regolisti G J Nephrol; 2019 Aug; 32(4):499-516. PubMed ID: 31119681 [TBL] [Abstract][Full Text] [Related]
8. [Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: Analysis of French data from the PROKALE multinational European study]. Rossignol P; Nephrol Ther; 2021 Oct; 17(6):422-427. PubMed ID: 33994135 [TBL] [Abstract][Full Text] [Related]
9. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia. Gorriz JL; D'Marco L; Pastor-González A; Molina P; Gonzalez-Rico M; Puchades MJ; Sanchis I; Escudero V; Estañ N; de la Espriella R; Nuñez E; Pallardó L; Núñez J Nephrol Dial Transplant; 2022 Feb; 37(3):522-530. PubMed ID: 33508124 [TBL] [Abstract][Full Text] [Related]
10. Potassium control in chronic kidney disease: implications for neuromuscular function. Arnold R; Pianta TJ; Pussell BA; Endre Z; Kiernan MC; Krishnan AV Intern Med J; 2019 Jul; 49(7):817-825. PubMed ID: 30230667 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Abnormalities of Potassium Homeostasis in CKD. Palmer BF; Clegg DJ Adv Chronic Kidney Dis; 2017 Sep; 24(5):319-324. PubMed ID: 29031359 [TBL] [Abstract][Full Text] [Related]
12. Novel approaches to management of hyperkalaemia in kidney transplantation. Rizk J; Quan D; Gabardi S; Rizk Y; Kalantar-Zadeh K Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):27-37. PubMed ID: 33027094 [TBL] [Abstract][Full Text] [Related]
13. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Georgianos PI; Agarwal R Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100 [TBL] [Abstract][Full Text] [Related]
14. Management of Hyperkalemia: An Update for the Internist. Kovesdy CP Am J Med; 2015 Dec; 128(12):1281-7. PubMed ID: 26093176 [TBL] [Abstract][Full Text] [Related]
15. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - A population-based cohort study. Adelborg K; Nicolaisen SK; Hasvold P; Palaka E; Pedersen L; Thomsen RW PLoS One; 2019; 14(6):e0218739. PubMed ID: 31226134 [TBL] [Abstract][Full Text] [Related]
16. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Han SW; Won YW; Yi JH; Kim HJ Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126 [TBL] [Abstract][Full Text] [Related]
17. Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes. Gilligan S; Raphael KL Adv Chronic Kidney Dis; 2017 Sep; 24(5):315-318. PubMed ID: 29031358 [TBL] [Abstract][Full Text] [Related]
18. [Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches]. De Stefano T; Borrelli S; Garofalo C; Provenzano M; De Nicola L; Minutolo R; Conte G G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234232 [TBL] [Abstract][Full Text] [Related]
19. Consensus statement on the management of hyperkalaemia-An Asia-Pacific perspective. Yap DYH; Ma RCW; Wong ECK; Tsui MSH; Yu EYT; Yu V; Szeto CC; Pang WF; Tse HF; Siu DCW; Tan KCB; Chen WWC; Li CL; Chen W; Chan TM Nephrology (Carlton); 2024 Jun; 29(6):311-324. PubMed ID: 38403867 [TBL] [Abstract][Full Text] [Related]
20. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]